For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895).
External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial / Becherini, C., Meattini, I., Livi, L., Garlatti, P., Desideri, I., Scotti, V., Orzalesi, L., Sanchez, L.J., Bernini, M., Casella, D., Nesi, S., Nori, J., Bianchi, S., Pallotta, S., Marrazzo, L.. - In: TUMORI. - ISSN 0300-8916. - STAMPA. - 105:(2019), pp. 205-209. [10.1177/0300891618811278]
External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial
Becherini, Carlotta;Meattini, Icro;Livi, Lorenzo;Garlatti, Pietro;Desideri, Isacco;Scotti, Vieri;Orzalesi, Lorenzo;Sanchez, Luis Jose;Bernini, Marco;Nori, Jacopo;Bianchi, Simonetta;Pallotta, Stefania;Marrazzo, Livia
2019
Abstract
For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895).
| File | Dimensione | Formato | |
|---|---|---|---|
|
2019_Becherini et al_Tumori.pdf
Accesso chiuso
Descrizione: Paper
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
78.94 kB
Formato
Adobe PDF
|
78.94 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
